JP4682251B2 - 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド - Google Patents

改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド Download PDF

Info

Publication number
JP4682251B2
JP4682251B2 JP2008553389A JP2008553389A JP4682251B2 JP 4682251 B2 JP4682251 B2 JP 4682251B2 JP 2008553389 A JP2008553389 A JP 2008553389A JP 2008553389 A JP2008553389 A JP 2008553389A JP 4682251 B2 JP4682251 B2 JP 4682251B2
Authority
JP
Japan
Prior art keywords
peptide
seq
hiv
amino acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008553389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525051A5 (enExample
JP2009525051A (ja
Inventor
ドウイエル ジョフン
エル． ブライ ブリアン
イー． スクフネイデル ステプヘン
ズハング フイイ
エー． トベルモエス ニコライ
イー．ジョフンストン バルバラ
イー． フリエドリクフ パウル
Original Assignee
トリメリス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリメリス，インコーポレーテッド filed Critical トリメリス，インコーポレーテッド
Publication of JP2009525051A publication Critical patent/JP2009525051A/ja
Publication of JP2009525051A5 publication Critical patent/JP2009525051A5/ja
Application granted granted Critical
Publication of JP4682251B2 publication Critical patent/JP4682251B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008553389A 2006-02-02 2007-02-02 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド Expired - Fee Related JP4682251B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02
PCT/US2007/002990 WO2007097903A2 (en) 2006-02-02 2007-02-02 Hiv fusion inhibitor peptides with improved biological properties

Publications (3)

Publication Number Publication Date
JP2009525051A JP2009525051A (ja) 2009-07-09
JP2009525051A5 JP2009525051A5 (enExample) 2010-03-18
JP4682251B2 true JP4682251B2 (ja) 2011-05-11

Family

ID=38437849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553389A Expired - Fee Related JP4682251B2 (ja) 2006-02-02 2007-02-02 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド

Country Status (15)

Country Link
US (3) US7456251B2 (enExample)
EP (1) EP1989220B1 (enExample)
JP (1) JP4682251B2 (enExample)
CN (1) CN101415723B (enExample)
AR (2) AR059300A1 (enExample)
AT (1) ATE537183T1 (enExample)
AU (1) AU2007218025A1 (enExample)
CA (1) CA2651793C (enExample)
CY (1) CY1113115T1 (enExample)
DK (1) DK1989220T3 (enExample)
ES (1) ES2381631T3 (enExample)
NZ (1) NZ570300A (enExample)
PT (1) PT1989220E (enExample)
TW (1) TWI341844B (enExample)
WO (1) WO2007097903A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007218025A1 (en) 2006-02-02 2007-08-30 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
AU2009260479A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting HIV entry
AU2009281992A1 (en) * 2008-08-13 2010-02-18 New York Blood Center Combination therapy of HIV fusion/entry inhibitors targeting gp41
US8936789B2 (en) * 2008-10-16 2015-01-20 New York Bood Center, Inc. Immunoenhancer-linked oligomeric HIV envelope peptides
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
WO2010091373A2 (en) * 2009-02-09 2010-08-12 New York Blood Center, Inc. Trimeric hiv fusion inhibitors for treating or preventing hiv infection
EP2566493B1 (en) 2010-05-03 2015-03-04 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv
RU2014129907A (ru) * 2011-12-19 2016-02-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Ингибиторы слияния hiv с мембраной
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
AU2791792A (en) 1991-10-04 1993-05-03 Robert H. Cornett Approaching emergency vehicle warning system
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
JP3698721B2 (ja) 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
NZ311319A (en) 1995-06-07 2000-01-28 Trimeris Inc The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
ES2185595T5 (es) 1999-05-17 2009-12-17 Conjuchem Biotechnologies Inc. Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
ES2253375T3 (es) 2000-04-19 2006-06-01 Genentech, Inc. Formulaciones de liberacion sostenida.
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
CN101132812A (zh) 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
JP2007529522A (ja) * 2004-03-15 2007-10-25 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１由来ペプチドの部位特異的化学修飾
AU2007218025A1 (en) 2006-02-02 2007-08-30 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties

Also Published As

Publication number Publication date
CN101415723A (zh) 2009-04-22
US20070179278A1 (en) 2007-08-02
TW200806687A (en) 2008-02-01
EP1989220A4 (en) 2009-05-06
US7456251B2 (en) 2008-11-25
AR059300A1 (es) 2008-03-26
CA2651793A1 (en) 2007-08-30
EP1989220B1 (en) 2011-12-14
CY1113115T1 (el) 2016-04-13
ES2381631T3 (es) 2012-05-30
AR108277A2 (es) 2018-08-01
US20120040891A1 (en) 2012-02-16
ATE537183T1 (de) 2011-12-15
CA2651793C (en) 2015-07-07
DK1989220T3 (da) 2012-04-02
PT1989220E (pt) 2012-03-23
TWI341844B (en) 2011-05-11
US8034899B2 (en) 2011-10-11
US20090105143A1 (en) 2009-04-23
CN101415723B (zh) 2014-06-25
WO2007097903A3 (en) 2008-05-22
WO2007097903A2 (en) 2007-08-30
AU2007218025A1 (en) 2007-08-30
EP1989220A2 (en) 2008-11-12
NZ570300A (en) 2011-08-26
JP2009525051A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
JP4682251B2 (ja) 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
KR20100016142A (ko) 항바이러스 펩티드 치료제 전달용 신규 제제
CN106749558B (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
CN111944025B (zh) 艾滋病病毒膜融合抑制剂脂肽及药物用途
KR20070006708A (ko) ＨＩＶ ｇｐ41 ＨＲ2-유래된 합성 펩티드 및 인간 면역결핍바이러스의 전염을 저해하는 치료에서 이들의 용도
AU2017410525B2 (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
US20100261876A1 (en) Novel methods of synthesis for therapeutic antiviral peptides
WO2018141089A1 (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
OA19487A (en) Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof.
MXPA06007675A (en) HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100127

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100127

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110207

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees